Choosing the right cell model is critical for reproducible, translatable results. This paper provides a decision matrix comparing commonly used models (primary cells, immortalized lines, iPSCs, organoids, microfluidic chips). We include failure case analyses (e.g., why a drug works in Caco-2 cells but fails in human trials) and a protocol for validating model “fidelity” using transcriptomic alignment with primary human tissue. The appendix contains a one-page lab reference card.
Sex chromosome complement (XX vs XY) influences cellular physiology independently of hormonal status. This paper provides a protocol for establishing primary and induced pluripotent stem cell (iPSC)-derived XX cell models, including quality controls (karyotyping, X-inactivation status). We demonstrate their utility in identifying sex-specific drug toxicities and modeling autoimmune disorders (e.g., lupus, more common in XX individuals). Researchers can apply this framework to reduce male bias in preclinical studies.
To give you something immediately useful, I’ll assume two likely meanings and provide a structured paper outline for each. You can confirm which one fits your needs. Paper Title: Developing and Validating XX Cell Models for Sex-Based Differences in Drug Metabolism and Disease Progression